A new implantable pump system safely and effectively bypasses the blood-brain barrier to deliver chemotherapy drugs to those with glioblastoma brain cancer.
Using gene editing to boost the production of SOD3 in the choroid plexus reduced oxidative damage to brain tissue and cerebral spinal fluid in mice exposed to methotrexate.
Researchers have uncovered the molecular mechanisms behind cognitive deficits and brain fog associated with chemotherapy, and identified a current FDA-approved drug for multiple sclerosis that can help reduce chemotherapy-induced cognitive impairments.
Neurofeedback has the potential to alleviate symptoms of "brain fog" and cognitive impairments associated with chemotherapy.
Hypermutation in children may be linked to increased mutations in the sperm of the biological father, especially fathers who received certain forms of chemotherapy to treat cancer early in life.
Axitinib, a chemotherapy drug that inhibits the growth of new blood vessels in the brain, improved memory and cognition in mouse models of Alzheimer's disease.
Changes in taste perception can for years following chemotherapy and radiotherapy treatments for cancer, a new study reports. Cancer survivors reported less sensitivity to bitter, sweet, and salty tastes compared to those who never received a cancer diagnosis. Taste buds on the tip of the tongue are most affected.
A newly developed ion pump can deliver cancer-fighting drugs more accurately, and with fewer side effects than conventional chemotherapy, to those with glioblastoma brain cancer.
Administering the chemotherapy drug temozolomide to glioblastoma brain cancer patients in the morning may enhance the cancer-fighting effects. The study demonstrates the timing of chemotherapy could have a significant impact on treatment for glioblastoma patients.
Heating up cancer cells as they are being targeted with chemotherapy appears to be a highly effective way of killing them off.
Cancer itself, rather than chemotherapy alone, may contribute to the development of neuropathy some patients experience.
Glioma patients whose tumors were hypermutated showed no significant benefit when treated with checkpoint blockers.
